Valneva (NASDAQ:VALN) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Valneva (NASDAQ:VALN) in a report released on Monday morning, Benzinga reports. HC Wainwright currently has a $26.00 price target on the stock.

Separately, Guggenheim reduced their price objective on Valneva from $18.00 to $17.00 and set a buy rating on the stock in a research note on Friday, March 22nd.

Valneva Stock Up 8.8 %

VALN opened at $7.81 on Monday. Valneva has a 1 year low of $6.58 and a 1 year high of $16.49. The firm has a 50 day moving average price of $8.00 and a 200 day moving average price of $8.38. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.22 and a current ratio of 2.64. The company has a market cap of $543.87 million, a PE ratio of -19.05 and a beta of 2.28.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.12. The company had revenue of $35.56 million during the quarter, compared to analyst estimates of $95.80 million. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. Sell-side analysts expect that Valneva will post -0.56 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. increased its position in shares of Valneva SE (NASDAQ:VALN) by 2.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 354,361 shares of the company’s stock after buying an additional 9,361 shares during the period. General American Investors Co. Inc. owned about 0.51% of Valneva worth $2,831,000 at the end of the most recent reporting period. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.